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28 Abstract
29 Transdifferentiation of beta- to alpha-cells has been implicated in the pathogenesis of 
30 diabetes. To investigate the impact of contrasting aetiologies of beta-cell stress, as well as 
31 clinically approved incretin therapies on this process, lineage tracing of beta-cells in 
32 transgenic Ins1Cre/+/Rosa26-eYFP mice was investigated. Diabetes-like syndromes were 
33 induced by streptozotocin (STZ), high fat feeding (HFF) or hydrocortisone (HC), and effects 
34 of treatment with liraglutide or sitagliptin investigated. Mice developed the characteristic 
35 metabolic features associated with beta-cell destruction or development of insulin resistance. 
36 Liraglutide was effective in preventing weight gain in HFF mice, with both treatments 
37 decreasing energy intake in STZ and HC mice. Treatment intervention also significantly 
38 reduced blood glucose levels in STZ and HC mice, as well as increasing either plasma or 
39 pancreatic insulin while decreasing circulating or pancreatic glucagon in all models. The 
40 recognised changes in pancreatic morphology induced by STZ, HFF or HC were partially, or 
41 fully, reversed by liraglutide and sitagliptin, and related to advantageous effects on alpha- and 
42 beta-cell growth and survival. More interestingly, induction of diabetes-like phenotype, 
43 regardless of pathogenesis, led to increased numbers of beta-cells losing their identity, as well 
44 as decreased expression of Pdx1 within beta-cells. Both treatment interventions, and 
45 especially liraglutide, countered detrimental islet cell transitioning effects in STZ and HFF 
46 mice. Only liraglutide imparted benefits on beta- to alpha-cell transdifferentiation in HC 
47 mice. These data demonstrate that beta- to alpha-cell transdifferentiation is a common 
48 consequence of beta-cell destruction or insulin resistance, and that clinically approved 




Page 2 of 32Accepted Manuscript published as JOE-19-0451.R1. Accepted for publication: 23-Jan-2020
Copyright © 2019 Society for Endocrinology Downloaded from Bioscientifica.com at 01/30/2020 11:46:36AM




55 The pathogenesis of diabetes is complex, involving many processes that ultimately results in 
56 pancreatic beta-cell dysfunction and/or development of peripheral insulin resistance [Weir et 
57 al. 2004].  The deficit of beta-cell mass and function in diabetes is not well understood, and 
58 has been linked to a loss of beta-cell identity, but related mechanism prove difficult to 
59 investigate [Accili et al. 2010; Kitamura, 2013]. However, recent advances in cell lineage 
60 tracing technologies has shed light on the process of pancreatic beta-cells transitioning from 
61 their mature state to become dedifferentiated or transdifferentiated into other cell types 
62 [Collombat et al. 2007; 2009; Thorel et al. 2010; Huising et al. 2018]. As such, beta-cell 
63 dedifferentiation is defined as a loss of beta-cell components, usually associated with an 
64 increase in the expression of progenitor markers, resulting in reduced insulin secretion [Weir 
65 et al. 2013]. The related process of transdifferentiation is generally categorised as a fully 
66 differentiated islet cell, such as a beta-cell, losing its phenotype and converting to an entirely 
67 new islet endocrine like cell [Talchai et al. 2012; Rutter et al. 2015]. This process can occur 
68 directly, when an islet cell demonstrates a second hormone before losing expression of its 
69 initial hormone, or indirectly whereby an intermediate dedifferentiation stage occurs prior to 
70 transition to a new islet cell [van der Meulen and Huising, 2015].
71 Extreme experimental conditions can been used to provoke and study 
72 transdifferentiation of islet cells in rodents. This includes chemically-induced beta-cell 
73 ablation [Thorel et al. 2010] or through altering the expression of specific islet cell 
74 transcription factors such as aristaless-related homeobox (Arx) [Courtney et al. 2013], paired 
75 box gene 4 (Pax4) [Collombat et al. 2007], pancreatic and duodenal homeobox 1 (Pdx-1) or 
76 forkhead box O1 (FOXO1) [Talchai et al. 2012]. Expression of such transcription factors are 
77 known to be vital in maintaining differentiated islet cell phenotypes [Gu et al. 2010; Gao et 
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78 al. 2014; Taylor et al. 2015; Hart et al. 2015]. As such, natural loss of beta-cell FOXO1 
79 expression during aging results in increased susceptibility to diabetes due to beta-cell 
80 dedifferentiation [Kitamura et al. 2013]. Importantly, these processes are not restricted to 
81 rodents, with dedifferentiation and transdifferentiation being observed in vitro in human beta-
82 cells [Gershengorn, et al. 2004; Weinberg et al. 2007; Spikjer et al. 2013; Diedisheim et al. 
83 2018] and in islet cells harvested directly from type 2 diabetes mellitus (T2DM) patients 
84 [Cinti et al. 2015]. 
85 In this regard, beneficial effects of the incretin hormones, glucagon-like peptide-1 
86 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), in T2DM have been linked 
87 to direct positive effects at the level of the endocrine pancreas. This includes, but not limited 
88 to, potentiation of glucose-stimulated insulin secretion, promotion of beta-cell growth, 
89 protection of beta cells from apoptosis and, in the case of GLP-1, suppression of glucagon 
90 secretion [Mest et al. 2005; Baggio and Drucker, 2007]. In addition, incretin peptides have 
91 been shown to upregulate expression levels of islet cell transcription factors involved in 
92 maintenance of beta-cell identity [Wei & Hong, 2019]. Thus, preliminary studies have 
93 examined the effects of GLP-1, but not GIP, on islet cell transdifferentiation in diabetes [Wei 
94 & Hong, 2019], with suggestion of favourable outcomes. To fully address this concept, the 
95 current study has employed transgenic Ins1Cre/+/Rosa26-eYFP mice [Thorens et al. 2015] to 
96 directly investigate beta- to alpha-cell transdifferentiation under contrasting diabetes-like 
97 aetiologies, including multiple low dose streptozotocin (STZ) or hydrocortisone (HC) 
98 administration, as well as prolonged high fat feeding. In addition, we also explored the 
99 impact of pharmacological upregulation of incretin receptor signalling pathways in each 
100 rodent model, through sub-chronic administration of the clinically approved GLP-1 receptor 
101 agonist, liraglutide, or the didpeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin. Together 
102 these studies unequivocally demonstrate the consequence of diabetes on islet cell 
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103 differentiation and the potential beneficial role of incretin receptor signalling on these 
104 processes. 
105
106 Material and Methods
107 Animals
108 Ins1Cre/+/Rosa26-eYFP C57BL/6 mice (Jackson Laboratories, Maine, USA) were bred in 
109 house at the Biomedical and Behavioural Research Unit (BBRU) at Ulster University, 
110 Coleraine. The original background of these mice has been characterised by Thorens et al. 
111 [2015]. Mice were housed individually in a temperature controlled room (22±2°C) on a 
112 regular 12 hour light/dark cycle. Standard chow (Trouw Nutrition, Norwich, UK) and 
113 drinking water were available ad libitum. All in vivo experiments were approved by Ulster 
114 University Animal Ethics Review Committee and conducted in accordance to the UK 
115 Animals (Scientific Procedures) Act 1986. Diabetes-like symptoms were induced in male 
116 mice (n=6) using STZ, HC or high fat feeding. 
117 Our studies were appropriately powered (n=6) to ensure robust and reproducible findings, 
118 using minimal numbers of animals, in line with the guiding principles of more ethical use of 
119 animals in research. In brief, STZ (50 mg/kg) was given to 12 week old mice on 5 
120 consecutive days by intraperitoneal (i.p.) injection in citrate buffer, inducing symptoms of 
121 insulin deficiency 5 days after the final injection. HC (70 mg/kg) was administered to 12 
122 week old mice on 10 consecutive days by i.p. injection, to induce insulin resistance. In both 
123 models, twice daily i.p. administration of liraglutide (25 nmol/kg) or once daily oral 
124 administration of sitagliptin (50 mg/kg) was commenced 2-3 days prior to administration of 
125 STZ or HC and continued until the end of the respective study period. For high-fat feeding 
126 studies, 4 week old mice were maintained on a high fat diet (45% fat) until 15 weeks of age 
127 to induce obesity and insulin resistance. These mice were similarly dosed with liraglutide (25 
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128 nmol/kg, i.p.; BID) or sitagliptin (50 mg/kg, p.o.) for an additional 12 days. The doses of 
129 liraglutide and sitagliptin were selected on the basis of previous studies [Gault et al. 2015; 
130 O’Harte et al. 2018]. For all studies, groups of 6-8 mice were used together with appropriate 
131 saline treated controls. Body weight, energy intake and non-fasting blood glucose were 
132 determined at regular intervals. Energy intake was assessed by manually determining 
133 consumption of respective diet for each mouse, and then using kJ/g energy content to 
134 extrapolate energy intake. Blood glucose measured from a tail vein blood spot using an 
135 Ascencia Contour Blood Glucose Meter (Bayer Healthcare, Newbury, UK). Terminal blood 
136 samples were taken for biochemical analyses and immunohistochemistry.
137
138 Biochemical analyses 
139 Snap frozen pancreatic tissues were homogenised in acid ethanol (ethanol (75% (v/v) ethanol, 
140 5% (v/v) distilled water and 1.5% (v/v) 12N HCl) and protein extracted in a pH neutral TRIS 
141 buffer. Protein content was determined using Bradford reagent (Sigma-Aldrich, Dorset, UK). 
142 Plasma and pancreatic insulin content was determined by an in-house insulin 
143 radioimmunoassay [Flatt & Bailey 1981]. Plasma and pancreatic glucagon content was 
144 determined by ELISA (glucagon chemiluminescent assay, EZGLU-30K, Millipore) following 
145 the Manufacturers guidelines.
146
147 Immunohistochemistry
148 Upon termination of studies, pancreatic tissues were excised and fixed in 4% PFA for 48 
149 hours at 4°C. Tissues were processed and embedded in paraffin wax blocks using an 
150 automated tissue processor (Leica TP1020, Leica Microsystems, Nussloch, Germany) and 5 
151 µm sections were cut on a microtome (Shandon finesse 325, Thermo scientific, UK). For 
152 immunohistochemistry, slides were dewaxed by immersion in xylene and rehydrated through 
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153 a series of ethanol solutions (100-50%). Heat mediated antigen retrieval was then carried out 
154 in citrate buffer. Sections were blocked in 4% BSA solution before 4°C overnight incubation 
155 with the following primary antibodies (Table 1), as appropriate, mouse monoclonal anti-
156 insulin (ab6995, 1:400; Abcam), guinea-pig anti-glucagon (PCA2/4, 1:400; raised in-house), 
157 rabbit anti-Ki67 (ab15580, 1:500; Abcam), rabbit anti-Pdx1 (ab47267, 1:200; Abcam) and 
158 goat anti-GFP antibody (ab5450, 1:1000; Abcam). Following this, slides were rinsed in PBS 
159 and incubated for 45 minutes at 37°C with appropriate secondary antibodies (Table 1) 
160 including, Alexa Fluor488 goat anti-guinea pig IgG, Alexa Fluor594 goat anti-mouse IgG, 
161 Alexa Fluor488 goat anti-rabbit IgG, Alexa Fluor594 goat anti-rabbit IgG or Alexa Fluor488 
162 donkey anti-goat IgG. Slides were finally incubated with DAPI for 15 mins at 37°C, and then 
163 mounted for imaging using a fluorescent microscope (Olympus system microscope, model 
164 BX51) fitted with DAPI (350 nm) FITC (488 nm) and TRITC (594 nm) filters and a DP70 
165 camera adapter system. As such, DAPI nuclear staining was used to ensure only viable cells 
166 were analysed, and exclude artefacts such as cell stacking within our image analysis. To 
167 assess cellular apoptosis a TUNEL assay was carried out following the Manufacturer’s 
168 guidelines (In situ cell death kit, Fluorescein, Roche Diagnostics, UK). 
169
170 Image analysis 
171 CellF imaging software (Olympus Soft Imaging Solutions, GmbH) was used to analyse the 
172 following islet parameters: islet-, beta- and alpha-cell areas. For transdifferentiation, cells 
173 expressing GFP with no insulin were termed ‘insulin-ve, GFP+ve’ cells, whilst islet cells co-
174 expressing GFP with glucagon were termed ‘glucagon+ve, GFP+ve" cells. To quantify 
175 apoptosis, beta- and alpha-cells co-expressing TUNEL alongside insulin and glucagon 
176 respectively were counted. Similarly, for proliferation, Ki-67 and insulin or glucagon positive 
177 cells were recorded. To assess Pdx1 expression, the number of Pdx1/insulin positive cells 
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178 were quantified and expressed as a percentage of total insulin expressing cells. All cell counts 
179 were determined in a blinded manner with >60 islets analysed per treatment group. 
180
181 Statistics 
182 Results were analysed using GraphPad PRISM (version 5), with data presented as mean ± 
183 SEM. Comparative analyses between groups were carried out using student’s unpaired t-test, 
184 one-way ANOVA with a Bonferroni post-hoc test or a two-way repeated measures ANOVA 




189 Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or 
190 sitagliptin administration, on body weight and energy intake in Ins1Cre/+/Rosa26-eYFP 
191 mice
192 All STZ mice displayed a decline (P<0.001) in body weight and overall percentage body 
193 weight change, with the greatest reduction observed in the sitagliptin treated group (Figure 
194 1A,B). All As a result of 15 weeks of high fat feeding prior to experimentation, all HFF mice 
195 presented with increased body weight when compared to lean controls (Figure 1D). In terms 
196 of percentage change in body weight over the 12-day treatment period, there was no 
197 difference between lean and HFF control mice, with only liraglutide significantly (P<0.001) 
198 decreasing this parameter (Figure 1E). Body weight was reduced (P<0.001) in HC-treated 
199 mice, and liraglutide or sitagliptin had no impact on this (Figure 1G,H). In addition, STZ 
200 mice exhibited decreased (P<0.05 – P<0.001) cumulative energy intake from day 4 onwards, 
201 with a further reduction (P<0.05 – P<0.001) evoked by treatment with liraglutide or 
202 sitagliptin (Figure 1C). Energy intake was consistently increased (P<0.05 – P<0.001) in HFF 
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203 mice, and liraglutide had a tendency to decrease this, but as with sitagliptin, was without 
204 significant effect (Figure 1F). HC mice presented with significantly (P<0.05) increased 
205 energy intake on days 9 and 10, with significant (P<0.001) reductions induced by both 
206 liraglutide and sitagliptin treatments (Figure 1I).
207
208 Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or 
209 sitagliptin administration, on blood glucose as well as plasma and pancreatic insulin and 
210 glucagon in Ins1Cre/+/Rosa26-eYFP mice
211 STZ mice exhibited increased blood glucose from day 7 onwards, attaining concentrations of 
212 26.3 ± 1.4 vs. 8.3 ± 0.3 mmol/l in lean control mice by day 10 (Figure 2A). HFF and HC mice 
213 had no substantial change in blood glucose levels (Figure 2B-D). However, treatment with 
214 liraglutide or sitagliptin significantly (P<0.05 – P<0.001) reduced blood glucose levels in 
215 STZ and HC, but not HFF, mice (Figure 2A-D). In STZ mice, plasma (P<0.01) and 
216 pancreatic (P<0.001) insulin were reduced, with both incretin therapies returning these 
217 parameters to lean control levels (Figure 2E,F). High fat feeding increased (P<0.01) plasma 
218 insulin (Figure 2E), whilst both incretin therapies increased (P<0.001) pancreatic insulin 
219 content in HFF mice (Figure 2F). In HC mice, plasma and pancreatic insulin were both raised 
220 (P<0.01) with sitagliptin therapy further enhancing (P<0.05) plasma insulin (Figure 2E), and 
221 liraglutide reducing (P<0.01) pancreatic insulin (Figure 2F). Plasma glucagon was raised 
222 (P<0.05 – P<0.001) in all three mouse models (Figure 2G). Liraglutide significantly (P<0.01) 
223 reduced circulating glucagon levels in STZ and HFF mice, whereas sitagliptin elicited a 
224 decrease in HFF (P<0.01) and HC (P<0.05) mice (Figure 2G). Similarly, liraglutide fully, and 
225 sitagliptin partially, countered the elevated glucagon in STZ diabetes (Figure 2H). Liraglutide 
226 was also able to reduce (P<0.01) pancreatic glucagon in HC mice (Figure 2H). 
227
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228 Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or 
229 sitagliptin administration, on pancreatic islet morphology in Ins1Cre/+/Rosa26-eYFP 
230 mice
231 STZ mice displayed reduced (P<0.01) islet and beta-cell areas (Figure 3A,B), accompanied 
232 by increased (P<0.001) alpha-cell area (Figure 3C). Islet area in liraglutide (P<0.01) and 
233 sitagliptin (P<0.05) treated STZ mice was elevated, despite no significant differences in 
234 alpha- or beta-cell mass (Figure 3A-C). HFF mice presented with increases in islet, beta- and 
235 alpha-cell areas (Figure 3A-C). Sitagliptin elicited significant (P<0.05 – P<0.01) reductions 
236 in these three islet parameters (Figure 3A-C). Liraglutide treatment only reduced (P<0.05) 
237 beta-cell area (Figure 3B). HC mice had increased islet (P<0.01) and beta-cell (P<0.001) 
238 areas, with no change in alpha-cell area (Figure 3A-C). Liraglutide did not affect this pattern 
239 but sitagliptin treatment resulted in a small expansion (P<0.05) of alpha-cell area (Figure 3C). 
240 Representative images of pancreatic tissue stained fluorescently for insulin, glucagon and 
241 DAPI form STZ, HFF and HC diabetic mice Ins1Cre/+/Rosa26-eYFP mice, as well as those 
242 mice treated with liraglutide and sitagliptin, are shown in Figure 3D.
243
244 Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or 
245 sitagliptin administration, on beta-to-alpha cell transdifferentiation and Pdx1 
246 expression in Ins1Cre/+/Rosa26-eYFP mice 
247 All mouse models exhibited a greater (P<0.001) number of insulin negative, GFP positive 
248 cells, as well as glucagon positive, GFP positive islet cells (Figure 4A,B). Liraglutide 
249 significantly (P<0.05 - P<0.001) reduced numbers of both islet cell types in STZ and HFF 
250 mice, as well as glucagon positive, GFP positive cells in HC mice (Figure 4A,B). Sitagliptin 
251 had similar benefits in STZ mice, and also reduced (P<0.01) insulin negative, GFP positive 
252 cells in HFF mice (Figure 4A,B). Induction of all forms of diabetes reduced (P<0.001) Pdx1 
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253 expression in insulin positive cells (Figure 4C). This detrimental effect was reversed by 
254 liraglutide treatment in STZ and HC mice, and Pdx1/insulin co-staining was elevated 
255 (P<0.05) by liraglutide in HFF mice (Figure 4C). Sitagliptin also increased (P<0.001) 
256 Pdx1/insulin co-staining in STZ mice (Figure 4C). Representative images of islets co-stained 
257 with insulin or glucagon and GFP, as well as Pdx1 and insulin are shown in Figure 4D-F. 
258
259 Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or 
260 sitagliptin administration on alpha- and beta-cell proliferation and apoptosis in 
261 Ins1Cre/+/Rosa26-eYFP mice 
262 Each mouse model exhibited increased (P<0.05 – P<0.001) beta- and alpha-cell apoptosis 
263 (Figure 5A,B). In terms of beta-cells, liraglutide and sitagliptin therapies significantly 
264 (P<0.05 – P<0.001) reduced apoptosis in STZ, HFF and HC mice (Figure 5A). For alpha-
265 cells, only liraglutide reduced apoptotic cell numbers, and this was evident only in STZ 
266 (P<0.05) and HC (P<0.001) mice (Figure 5B). Indeed, liraglutide returned alpha-cell 
267 apoptosis to lean control levels in STZ mice (Figure 5B). High fat feeding (P<0.01) and HC 
268 (P<0.001) increased beta-cell proliferation, whereas STZ (P<0.001) and high fat feeding 
269 (P<0.05) increased alpha-cell growth (Figure 6A,B). Liraglutide dramatically increased 
270 (P<0.001) beta-cell proliferation in STZ mice, but lacked significant effects in HFF and HC 
271 mice (Figure 6A). Sitagliptin did not affect beta-cell proliferation in any of the mice (Figure 
272 6A). However, sitagliptin did significantly decrease (P<0.05) alpha-cell growth in STZ and 
273 HFF mice, whereas liraglutide was without significant effect (Figure 6B). Representative 
274 images of islets co-stained with TUNEL and insulin (Figure 5C) or glucagon (Figure 5D), as 
275 well as Ki-67 with insulin (Figure 6C) or glucagon (Figure 6D) are also shown
276
277 Discussion 
Page 11 of 32 Accepted Manuscript published as JOE-19-0451.R1. Accepted for publication: 23-Jan-2020
Copyright © 2019 Society for Endocrinology Downloaded from Bioscientifica.com at 01/30/2020 11:46:36AM
via Univ of Ulster At Coleraine
12
278 All major forms of diabetes are linked to pancreatic beta-cell loss over time, which represents 
279 an ideal therapeutic target for this disease [Donath and Halben, 2004; Eizirik et al. 2009]. In 
280 this regard, GLP-1 mimetics currently administered to T2DM patients have been shown to 
281 increase beta-cell mass in rodents through proliferation and/or neogenesis of beta-cells 
282 [Moffett et al. 2014], that is presumably linked to upregulation of important beta-cell 
283 transcription factors such as Pdx1 [Li et al. 2005; Yang et al. 2011; Gao et al. 2014]. In 
284 addition, inhibition of beta-cell apoptosis is a notable feature of GLP-1 receptor activation at 
285 the level of the endocrine pancreas [Farilla et al. 2003; Moffett et al. 2014]. Moreover, recent 
286 evidence suggests that GLP-1 could augment the process of alpha- to beta-cell 
287 transdifferentiation [Zhang et al. 2019]. Additional studies are required to confirm this 
288 therapeutically relevant biological action using appropriate experimental tools such as 
289 transgenic Ins1Cre/+/Rosa26-eYFP mice [Thorens et al. 2015]. Further to this, although the 
290 sister incretin hormone of GLP-1, namely GIP, also induces notable direct beta-cell benefits 
291 [Trumper et al. 2002, Ehses et al. 2002], there is an absence of knowledge on the impact of 
292 clinically approved DPP-4 inhibitor drugs, that augment circulating levels of GIP and GLP-1, 
293 on pancreatic islet cell transdifferentiation. 
294 In the current study, diabetes-like syndromes with contrasting aetiologies were 
295 induced in Ins1Cre/+/Rosa26-eYFP mice, through administration of STZ, HC or prolonged 
296 high fat (45%) feeding. These transgenic mice displayed the classic features related to either 
297 beta-cell destruction or insulin resistance [Vasu et al. 2014]. As expected, the presenting 
298 metabolic characteristics and associated pancreatic morphology differed between each mouse 
299 model [Vasu et al. 2014]. Thus, STZ mice exhibited hyperglycaemia-insulin deficiency, 
300 whereas HFF and HC induced marked hyperinsulinaemia-insulin resistance. All mice 
301 consistently exhibited a remarkable increase in the number of pancreatic beta-cells losing 
302 their identity, as well as the number of mature insulin-secreting beta-cells transitioning to 
Page 12 of 32Accepted Manuscript published as JOE-19-0451.R1. Accepted for publication: 23-Jan-2020
Copyright © 2019 Society for Endocrinology Downloaded from Bioscientifica.com at 01/30/2020 11:46:36AM
via Univ of Ulster At Coleraine
13
303 glucagon positive cells. There appeared to a correlation between numbers of insulin negative, 
304 GFP positive and glucagon positive, GFP positive islet cells. This suggests that, within the 
305 limitations of immunohistochemical co-localisation, a clear islet cell transdifferentiation route 
306 seems to exist.  This islet cell differentiation effect was consistently associated with 
307 decreased beta-cell Pdx1 expression. Such observations clearly indicate that beta-cell 
308 dysregulation and insulin resistance are linked to detrimental alteration of pancreatic islet cell 
309 differentiation [Talchai et al. 2012], regardless of disease pathogenesis. Given that T2DM 
310 patients have low levels of beta-cell apoptosis [Butler et al. 2007], this would suggest that the 
311 beta-cell deficit in this disease is connected to beta-cell dedifferentiation or adverse beta-cell 
312 transdifferentiation [Huising et al. 2018]. Thus, beta- to alpha-cell transdifferentiation 
313 appears to be a normal phenomenon that is amplified in diabetes. The extent to which this 
314 amplification process plays in the induction and progression of diabetes still needs to be fully 
315 clarified, but our observations suggest at least some involvement. Furthermore, additional 
316 studies are required to determine whether the former beta-cells retain the beta-cell glucose 
317 sensing behaviour whilst secreting glucagon instead. These factors are of particular relevance 
318 in terms of therapeutic interventions, suggesting that antidiabetic drugs positively targeting 
319 islet cell differentiation pathways are likely to induce more effective and sustainable benefits 
320 in humans.
321 In all three mouse models both liraglutide and sitagliptin maintained or elevated 
322 circulating insulin and decreased plasma glucagon concentrations, while concomitantly 
323 reducing blood glucose in STZ and HC mice, in keeping with their notable antidiabetic 
324 actions [Drucker and Nauck, 2006]. Lack of obvious effect of liraglutide and sitagliptin on 
325 glucose levels in HFF mice is likely related to, absence of hyperglycaemia and the timing of 
326 commencement, and duration, of the treatment interventions. As such, treatment was initiated 
327 in HFF mice following 15 weeks of high (45%) fat feeding, where obesity, hyperinsulinaemia 
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328 and related insulin resistance were already manifest. In STZ and HC mice, treatment 
329 intervention began prior to induction of the diabetes-like phenotypes. It should also be noted 
330 that both HFF and HC mice did not present with overt hyperglycaemia, and this is likely due 
331 to their prominent hyperinsulinaemia, and related elevated pancreatic beta-cell areas, that was 
332 able to offset the recognised insulin resistance in these mouse models [Vasu et al. 2014]. 
333 Liraglutide was perhaps more effective in terms of correcting the changes in glucagon, 
334 glucose and insulin, and this is could be related to higher circulating GLP-1 levels induced by 
335 this treatment regimen [Ghanim et al. 2019]. Indeed, the overall antidiabetic effectiveness of 
336 DPP-4 inhibitors is suggested to be slightly less striking than other clinically approved drugs 
337 [Rosenstock et al. 2010]. In keeping with this, only liraglutide was able to counter weight 
338 gain induced by high fat feeding [Porter et al. 2010], with none of the treatment interventions 
339 positively affecting body weight in STZ or HC diabetic mice. This being despite reduced 
340 energy intake in liraglutide and sitagliptin treated STZ and HC mice, and no significant 
341 impact of the treatments on energy intake in HFF mice. As such, differences in disease 
342 aetiologies [Vasu et al. 2014], and the influence and plasticity of GLP-1 receptor activation 
343 on central pathways linked to energy homeostasis [Porter et al. 2010], are likely important in 
344 accounting for such changes. 
345 Pancreatic islet areas were retuned toward lean control levels by both incretin 
346 treatment modalities in STZ and HFF mice, consistent with established antidiabetic efficacy 
347 [Vasu et al. 2014]. Interestingly, although STZ and HFF mice had elevated alpha-cell area, 
348 pancreatic glucagon concentrations were actually reduced in HFF mice, with sitagliptin 
349 inducing a further decrease in both parameters. Similarly, liraglutide and sitagliptin decreased 
350 pancreatic glucagon content, without affecting alpha-cell area, in STZ mice. Encouragingly 
351 however, both the GLP-1 mimetic and DPP-4 inhibitor drugs decreased circulating glucagon 
352 in STZ and HFF mice, in line with beneficial antidiabetic glucagonostatic effects of GLP-1 
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353 receptor activation [Lund et al. 2011]. In addition, liraglutide and sitagliptin increased 
354 circulating and pancreatic insulin in both mouse models [Gault et al. 2015; O’Harte et al. 
355 2018], and were especially effective in STZ diabetic mice. Together with decreased 
356 glucagon, this could support the notion that incretin receptor activation may prevent or inhibit 
357 beta- to alpha-cell transdifferentiation, and foster alpha- to beta-cell transitioning. 
358 Indeed, in STZ mice, both incretin-based treatments limited the number of islet cells 
359 converting from beta- to alpha-phenotypes and helped maintain beta-cell identity and 
360 maturity by upholding Pdx1 expression [Gao et al. 2014]. Given the similarity in 
361 effectiveness of liraglutide and sitagliptin in this regard, it might suggest that increasing GIP 
362 alongside GLP-1 provides no additive benefit on islet cell differentiation. However, analysis 
363 of circulating concentrations of GIP and GLP-1 would be required to confirm this concept. In 
364 addition, islet alpha-cells are known to produce both GLP-1 and GIP under conditions of islet 
365 stress [Moffett et al. 2014] and positive effects of sitagliptin within islets cannot be ruled out. 
366 Similar favourable observations on differentiation of islet cells were also made in HFF mice 
367 treated with liraglutide and sitagliptin, albeit sitagliptin was only capable of provoking non-
368 significant decreases in the number of beta-cells transdifferentiating towards alpha-cells and 
369 augmenting Pdx1 expression in beta-cells. Improvements in glycaemic status have been 
370 shown to prevent beta-to alpha-cell transdifferentiation as well as reversing beta-cell 
371 dedifferentiation [Wang et al. 2014], and importantly islet cell differentiation effects were 
372 independent of changes of circulating glucose in HFF mice. Further to this, clear benefits of 
373 liraglutide and sitagliptin to inhibit beta-cell apoptosis [Maida et al. 2009; Takeda et al. 
374 2012], as well as promote beta-cell growth in STZ mice [Hendarto et al. 2012], could be 
375 important in terms of overall pancreatic architectural effects. However, reduced alpha-cell 
376 apoptosis, coupled with unaltered alpha-cell area and proliferation in liraglutide treated STZ 
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377 mice, is highly suggestive of alpha- to beta-cell transdifferentiation benefits of this GLP-1 
378 mimetic.  
379 In HC mice, general pancreatic islet architecture was not remarkably altered by 
380 concurrent liraglutide or sitagliptin treatment, barring a small increase in alpha-cell area 
381 induced by the DPP-4 inhibitor drug. Interestingly, in humans DPP-4 is believed to be 
382 expressed at high levels in alpha-cells [Augstein et al. 2015], which may partly explain this 
383 finding. However, others have shown the enzyme to be readily expressed in human 
384 pancreatic beta-cells, with direct inhibition improving cell function and survival [Bugliani et 
385 al. 2018]. Despite this, effects of liraglutide and sitagliptin on islet cell transdifferentiation 
386 were minimal in HC mice, aside from the GLP-1 mimetic marginally reducing diabetes-
387 induced loss of beta-cell identity. Liraglutide substantially decreased beta-cell apoptosis in 
388 HC mice and augmented Pdx1 expression, but alpha-cell apoptosis was also reduced which 
389 may offset this benefit, especially since islet cell proliferation was unaltered by liraglutide. 
390 Thus, in this context, incretin type drugs may be less effective for cases of diabetes linked to 
391 altered glucocorticoid metabolism [Pivonello et al. 2010]. However, in contrast to this notion, 
392 both incretin treatments reduced circulating glucose to levels below that of lean control mice, 
393 in keeping with knowledge that glucocorticoids can decrease GLP-1 secretion and action 
394 [Van Raalte et al. 2011].
395 In conclusion, the present studies highlight similar alterations of pancreatic islet cell 
396 differentiation in three well-characterised mouse models of beta-cell loss, insulin resistance 
397 and diabetes that exhibit contrasting aetiologies. As such, STZ, HFF and HC mice presented 
398 with increased beta- to alpha-cell transdifferentiation, demonstrating this process as an 
399 authentic characteristic associated with diabetes. Notably, liraglutide, and to lesser extent 
400 sitagliptin, exerted positive effects on beta-cell transdifferentiation particularly in STZ and 
401 HFF mice, as well as promoting growth and survival of these cells. Such actions emphasise 
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402 the potential of incretin enhancer drugs for beta-cell restoration and subsequent promotion of 
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634 Figure 1. Effects of STZ-, HFF- and HC-treatment alone, and in combination with 
635 liraglutide or sitagliptin administration, on body weight and energy intake in 
636 Ins1Cre/+/Rosa26-eYFP mice. Body weight, percentage body weight change and energy 
637 intake was measured during and after 10 or 12 days, as appropriate, treatment with saline 
638 vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.) in (A,B,C) 
639 STZ, (D,E,F) HFF and (G,H,I) HC Ins1Cre/+/Rosa26-eYFP diabetic mice. Values represent 
640 mean ± SEM for 6 mice. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. 
641 ∆P<0.05, ∆∆P<0.01. ∆∆∆P<0.001 compared to respective STZ, HFF or HC controls.
642
643 Figure 2. Effects of STZ-, HFF- and HC-treatment alone, and in combination with 
644 liraglutide or sitagliptin administration, on non-fasting circulating glucose, insulin and 
645 glucagon as well as pancreatic insulin and glucagon content in Ins1Cre/+/Rosa26-eYFP 
646 mice. Blood glucose was assessed in (A) STZ, (B) HFF and (C) HC Ins1Cre/+/Rosa26-eYFP 
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647 diabetic mice for 3 days prior to, and 10 or 12 days during, as appropriate, treatment with 
648 saline vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). (D-H) 
649 Final circulating (D) blood glucose as well as plasma and pancreatic (E,F) insulin or (G,H) 
650 glucagon were measured at the end of the treatment period. Values represent mean ± SEM for 
651 6 mice. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. ∆P<0.05, ∆∆P<0.01. 
652 ∆∆∆P<0.001 compared to respective STZ, HFF or HC controls.
653
654 Figure 3. Effects of STZ-, HFF- and HC-treatment alone, and in combination with 
655 liraglutide or sitagliptin administration, on pancreatic morphology in Ins1Cre/+/Rosa26-
656 eYFP mice. (A-C) Parameters were assessed in STZ, HFF and HC Ins1Cre/+/Rosa26-eYFP 
657 diabetic mice after 10 or 12 days, as appropriate, treatment with saline vehicle, liraglutide 
658 (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). (A) Islet, (B) beta- and (C) alpha-
659 cell areas were measured using CellF image analysis software. (D) Representative images 
660 (40X) of islets showing insulin (red), glucagon (green) and DAPI (blue) immunoreactivity 
661 from each group of mice. Values are mean ± SEM for 6 mice, with approximately 80 islets 
662 per group analysed. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. ∆P<0.05, 
663 ∆∆P<0.01 compared to respective STZ, HFF or HC controls.
664
665 Figure 4. Effects of STZ-, HFF- and HC-treatment alone, and in combination with 
666 liraglutide or sitagliptin administration, on pancreatic beta-cell lineage and Pdx1 
667 expression in Ins1Cre/+/Rosa26-eYFP mice. (A-C) Parameters were assessed in STZ, HFF 
668 and HC Ins1Cre/+/Rosa26-eYFP diabetic mice after 10 or 12 days, as appropriate, treatment 
669 with saline vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). (D-
670 F) Representative images (40X) of islets showing (D) insulin (red), (E) glucagon (red) and 
671 (D,E) GFP (green), or (F) insulin (red) and Pdx1 (green) immunoreactivity from each group 
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672 of mice. Arrows indicate co-staining, as appropriate. Values are mean ± SEM for 6 mice, 
673 with approximately 80 islets per group analysed. *P<0.05, **P<0.01 and ***P<0.001 
674 compared to lean controls. ∆P<0.05, ∆∆P<0.01. ∆∆∆P<0.001 compared to respective STZ, HFF 
675 or HC controls.
676
677 Figure 5. Effects of STZ-, HFF- and HC-treatment alone, and in combination with 
678 liraglutide or sitagliptin administration, on pancreatic beta- and alpha-cell apoptosis in 
679 Ins1Cre/+/Rosa26-eYFP mice. (A,B) Parameters were assessed in STZ, HFF and HC 
680 Ins1Cre/+/Rosa26-eYFP diabetic mice after 10 or 12 days, as appropriate, treatment with saline 
681 vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). Pancreatic (A) 
682 beta- and (B) alpha-cell apoptosis were measured using TUNEL staining and quantified with 
683 ImageJ software. (C,D) Representative images (40X) of islets showing insulin or glucagon 
684 (both green), Ki-67 (red) and DAPI (blue) immunoreactivity from each group of mice. 
685 Arrows indicate co-staining, as appropriate. Values are mean ± SEM for 6 mice, with 
686 approximately 80 islets per group analysed. *P<0.05, **P<0.01 and ***P<0.001 compared to 
687 lean controls. ∆P<0.05, ∆∆P<0.01. ∆∆∆P<0.001 compared to respective STZ, HFF or HC 
688 controls.
689
690 Figure 6. Effects of STZ-, HFF- and HC-treatment alone, and in combination with 
691 liraglutide or sitagliptin administration, on pancreatic beta- and alpha-cell proliferation 
692 in Ins1Cre/+/Rosa26-eYFP mice. (A,B) Parameters were assessed in STZ, HFF and HC 
693 Ins1Cre/+/Rosa26-eYFP diabetic mice after 10 or 12 days, as appropriate, treatment with saline 
694 vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). Pancreatic (A) 
695 beta- and (B) alpha-cell proliferation were measured using Ki-67 staining and quantified with 
696 ImageJ software. (C,D) Representative images (40X) of islets showing insulin or glucagon 
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697 (both green), Ki-67 (red) and DAPI (blue) immunoreactivity from each group of mice. 
698 Arrows indicate co-staining, as appropriate. Values are mean ± SEM for 6 mice, with 
699 approximately 80 islets per group analysed. *P<0.05, **P<0.01 and ***P<0.001 compared to 
700 lean controls. ∆P<0.05, ∆∆P<0.01. ∆∆∆P<0.001 compared to respective STZ, HFF or HC 
701 controls.
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Table 1. Target, host, dilution factors and soured of primary and secondary antibodies 
employed for immunofluorescent studies
Primary Antibodies 
Target Host Dilution Source 
Insulin Mouse 1:400 Abcam (ab6995)
Glucagon Guinea-pig 1:400 Raised in-house (PCA2/4) 
GFP Goat 1:1000 Abcam (ab5450) 
Ki-67 Rabbit 1:500 Abcam (ab15580)
Pdx-1 Guinea-pig 1:200 Abcam (ab47308)
Secondary Antibodies 
Target Host Reactivity Dilution Source 
IgG, Alexa Fluor 594 Goat Mouse 1:400 Invitrogen, UK
IgG, Alexa Fluor 488 Goat Mouse 1:400 Invitrogen, UK
IgG, Alexa Fluor 594 Goat Guinea-pig 1:400 Invitrogen, UK
IgG, Alexa Fluor 488 Goat Guinea-pig 1:400 Invitrogen, UK  
IgG, Alexa Fluor 594 Goat Rabbit 1:400 Invitrogen, UK
IgG, Alexa Fluor 488 Goat Rabbit 1:400 Invitrogen, UK
IgG, Alexa Fluor 488 Donkey Goat 1:400 Invitrogen, UK
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Body Weight - STZ
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Blood Glucose - HC
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Lean Control STZ Control STZ + Liraglutide STZ + Sitagliptin HFF Control
HFF + Liraglutide HFF + Sitagliptin HC Control HC + Liraglutide HC + Sitagliptin
Insulin / Glucagon / DAPI
(A) (B) (C)
(D)
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Insulin / PDX1/ DAPI(F)
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(D)(C) Insulin / TUNEL Glucagon / TUNEL
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